Condition
Spinal Muscular Atrophy Type III
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Terminated1
Active Not Recruiting1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04042025Phase 3Active Not Recruiting
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
NCT06137612UnknownPrimary
Spinal Cord Gray Matter Imaging in Spinal Muscular Atrophy
NCT00439569Phase 1Terminated
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III
Showing all 3 trials